申请人:BORAGEN INC
公开号:WO2021003501A1
公开(公告)日:2021-01-07
The present disclosure describes novel compounds, or their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and their medical uses. Compounds of the disclosure have activity as dual modulators of Janus kinase (JAK), alone, or in combination with one or more of an additional mechanism, including a tyrosine kinase, such as TrkA or Syk, and PDE4, and are useful in the in the treatment or control of inflammation, auto-immune diseases, cancer, and other disorders and indications where modulation of JAK would be desirable. Also described herein are methods of treating inflammation, auto-immune diseases, cancer, and other conditions susceptible to inhibition of JAK and PDE4 by administering a compound herein described.
本公开描述了新颖的化合物,或其药用可接受的盐,含有它们的药物组合物,以及它们的医疗用途。本公开的化合物具有作为Janus激酶(JAK)的双重调节剂的作用,单独使用,或与一个或多个附加机制(包括酪氨酸激酶,如TrkA或Syk,以及PDE4)结合使用,并且在治疗或控制炎症、自身免疫疾病、癌症以及其他调节JAK会可取的失调和其他适应症中是有用的。此外,还描述了通过施用本处所述的化合物来治疗炎症、自身免疫疾病、癌症以及其他易受JAK和PDE4抑制的状况的方法。